Stephens Inc. AR Buys 2,938 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Stephens Inc. AR raised its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 27.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,655 shares of the biopharmaceutical company’s stock after acquiring an additional 2,938 shares during the quarter. Stephens Inc. AR’s holdings in Amicus Therapeutics were worth $111,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. boosted its position in Amicus Therapeutics by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company’s stock valued at $275,619,000 after acquiring an additional 458,143 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Amicus Therapeutics by 18.8% in the 4th quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company’s stock worth $268,112,000 after purchasing an additional 4,497,950 shares in the last quarter. Nuveen Asset Management LLC boosted its position in shares of Amicus Therapeutics by 4.4% in the 4th quarter. Nuveen Asset Management LLC now owns 3,807,420 shares of the biopharmaceutical company’s stock worth $35,866,000 after purchasing an additional 159,139 shares in the last quarter. Northern Trust Corp boosted its position in shares of Amicus Therapeutics by 5.9% in the 4th quarter. Northern Trust Corp now owns 3,371,639 shares of the biopharmaceutical company’s stock worth $31,761,000 after purchasing an additional 187,652 shares in the last quarter. Finally, Vestal Point Capital LP acquired a new stake in shares of Amicus Therapeutics in the 4th quarter worth $31,557,000.

Amicus Therapeutics Stock Performance

NASDAQ FOLD opened at $5.96 on Monday. The stock has a 50-day simple moving average of $6.07 and a two-hundred day simple moving average of $7.64. The firm has a market capitalization of $1.84 billion, a P/E ratio of -66.21 and a beta of 0.51. Amicus Therapeutics, Inc. has a fifty-two week low of $5.51 and a fifty-two week high of $12.65. The company has a debt-to-equity ratio of 2.02, a quick ratio of 2.47 and a current ratio of 3.34.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on FOLD. Morgan Stanley raised Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a research report on Thursday. The Goldman Sachs Group lowered their price objective on Amicus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a research report on Friday, May 2nd. Wall Street Zen cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, May 5th. Finally, UBS Group raised their price objective on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, May 2nd. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $16.22.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.